Informações:
Falhas:
ID
30950
Descrição
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA); ODM derived from: https://clinicaltrials.gov/show/NCT00937157
Link
https://clinicaltrials.gov/show/NCT00937157
Palavras-chave
Versões (1)
- 06/07/2018 06/07/2018 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
6 de julho de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Multiple Sclerosis NCT00937157
Eligibility Multiple Sclerosis NCT00937157
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis NCT00937157
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Multiple Sclerosis
Item
patients diagnosed with clinically definite ms according to the mcdonald criteria
boolean
C0026769 (UMLS CUI [1])
Gadolinium-Enhancing Lesion | Recurrent disease
Item
have a gd enhancing lesion using 1.5t standard protocol and/or an acute relapse
boolean
C1333400 (UMLS CUI [1])
C0277556 (UMLS CUI [2])
C0277556 (UMLS CUI [2])
Age
Item
age 18-65
boolean
C0001779 (UMLS CUI [1])
Multiple Sclerosis, Relapsing-Remitting | Clinically isolated syndrome | High risk of Multiple Sclerosis | Lesion Quantity | Gadolinium-Enhancing Lesion Quantity
Item
have a relapsing-remitting (rr) disease course or clinically isolated syndrome (cis) with high risk of conversion to clinically definite (cd) ms (presence of >9 t2 lesions in addition to 1 gd lesion)
boolean
C0751967 (UMLS CUI [1])
C2921627 (UMLS CUI [2])
C0332167 (UMLS CUI [3,1])
C0026769 (UMLS CUI [3,2])
C0221198 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C1333400 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C2921627 (UMLS CUI [2])
C0332167 (UMLS CUI [3,1])
C0026769 (UMLS CUI [3,2])
C0221198 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C1333400 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
EDSS
Item
have edss scores less than or equal to 5.5
boolean
C0451246 (UMLS CUI [1])
Disease length
Item
have disease duration of 3 months to 30 years
boolean
C0872146 (UMLS CUI [1])
Exclusion Criteria None
Item
none of the exclusion criteria
boolean
C0680251 (UMLS CUI [1,1])
C0549184 (UMLS CUI [1,2])
C0549184 (UMLS CUI [1,2])
Immunomodulation | Therapeutic immunosuppression | Interferon-beta | glatiramer acetate | Mitoxantrone | Cyclophosphamide | Cladribine | fludarabine | Cyclosporine | Whole-Body Irradiation | Azathioprine | Methotrexate | Immunoglobulins, Intravenous | Cellcept | natalizumab
Item
previous immunomodulatory or immunosuppressant treatment during the 30 days prior to day 0 of the study with the following agents (e.g., ifn-β, ga, mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine, total body, azathioprine, methotrexate, ivig, cellcept, natalizumab, etc.)
boolean
C1963758 (UMLS CUI [1])
C0021079 (UMLS CUI [2])
C0015980 (UMLS CUI [3])
C0289884 (UMLS CUI [4])
C0026259 (UMLS CUI [5])
C0010583 (UMLS CUI [6])
C0092801 (UMLS CUI [7])
C0059985 (UMLS CUI [8])
C0010592 (UMLS CUI [9])
C0043162 (UMLS CUI [10])
C0004482 (UMLS CUI [11])
C0025677 (UMLS CUI [12])
C0085297 (UMLS CUI [13])
C0592558 (UMLS CUI [14])
C1172734 (UMLS CUI [15])
C0021079 (UMLS CUI [2])
C0015980 (UMLS CUI [3])
C0289884 (UMLS CUI [4])
C0026259 (UMLS CUI [5])
C0010583 (UMLS CUI [6])
C0092801 (UMLS CUI [7])
C0059985 (UMLS CUI [8])
C0010592 (UMLS CUI [9])
C0043162 (UMLS CUI [10])
C0004482 (UMLS CUI [11])
C0025677 (UMLS CUI [12])
C0085297 (UMLS CUI [13])
C0592558 (UMLS CUI [14])
C1172734 (UMLS CUI [15])